TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Research from E. Badell and co-authors in the area of tuberculosis published
February 10th, 2009
"The potent IFN-gamma inducing fusion antigen Ag8513-ESAT-6 (85136) is a lead subunit candidate to improve current vaccination against Mycobacterium tuberculosis (Mtb). The recombinant M. bovis BCG strain Myc3504 was constructed to secrete 85B6. It was based on commercial BCG strain Moreau Rio de Janeiro (BCG(MoWT)) which remains available for human oral administration," scientists in Paris, France report. "Myc 3504 induced higher levels of 85B6-specific IFN-gamma circulating T-cells as compared to BCG(MowT). A novel needle-free mucosal immunization regimen combining oral prime with Myc3504 or BCG(MoWT) With intranasal boost with LTK-63-adjuvanted 85136 was compared to...
Source: TB & Outbreaks Week (2009-02-10)
|
